Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a... IntroductionPalmoplantar involvement in patients with psoriasis can severely impact quality of life and limit work productivity. Topical treatments generally have limited efficacy for moderate‐to‐severe palmoplantar psoriasis. Systemic treatments such as methotrexate, acitretin, tumour necrosis factor alpha (TNF‐α) inhibitors (etanercept, adalimumab and infliximab) and interleukin 17A or 12/23 inhibitors (secukinumab and ustekinumab) have been reported to be efficacious. However, their efficacy in palmoplantar psoriasis is usually lower than when they are used for psoriasis vulgaris. Only 30–40% of patients with moderate‐to‐severe palmoplantar psoriasis achieve a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 after 12–16 weeks of treatment with biologics. There is a need for the development of novel treatments for palmoplantar psoriasis.Apremilast is an oral phosphodiesterase inhibitor, that is approved for the treatment of psoriasis and psoriatic arthritis. A post hoc analysis of palmoplantar data from three phase 2 and 3 studies conducted in patients with moderate‐to‐severe psoriasis vulgaris suggested that apremilast could be effective for the treatment of psoriasis involving palms and soles. However, this analysis included all patients presenting at least a moderate severity based on physician global assessment of palmoplantar disease regardless of the surface area involved with palmoplantar psoriasis at baseline. This study evaluates the efficacy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Loading next page...
 
/lp/wiley/apremilast-for-the-treatment-of-moderate-to-severe-palmoplantar-7Gml0hewVF
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14647
Publisher site
See Article on Publisher Site

Abstract

IntroductionPalmoplantar involvement in patients with psoriasis can severely impact quality of life and limit work productivity. Topical treatments generally have limited efficacy for moderate‐to‐severe palmoplantar psoriasis. Systemic treatments such as methotrexate, acitretin, tumour necrosis factor alpha (TNF‐α) inhibitors (etanercept, adalimumab and infliximab) and interleukin 17A or 12/23 inhibitors (secukinumab and ustekinumab) have been reported to be efficacious. However, their efficacy in palmoplantar psoriasis is usually lower than when they are used for psoriasis vulgaris. Only 30–40% of patients with moderate‐to‐severe palmoplantar psoriasis achieve a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 after 12–16 weeks of treatment with biologics. There is a need for the development of novel treatments for palmoplantar psoriasis.Apremilast is an oral phosphodiesterase inhibitor, that is approved for the treatment of psoriasis and psoriatic arthritis. A post hoc analysis of palmoplantar data from three phase 2 and 3 studies conducted in patients with moderate‐to‐severe psoriasis vulgaris suggested that apremilast could be effective for the treatment of psoriasis involving palms and soles. However, this analysis included all patients presenting at least a moderate severity based on physician global assessment of palmoplantar disease regardless of the surface area involved with palmoplantar psoriasis at baseline. This study evaluates the efficacy

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial